247 related articles for article (PubMed ID: 22799876)
1. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Menn P; Leidl R; Holle R
Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
[TBL] [Abstract][Full Text] [Related]
2. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
3. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
Atsou K; Chouaid C; Hejblum G
PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of physical activity in the management of COPD patients in the UK.
Ramos M; Lamotte M; Gerlier L; Svangren P; Miquel-Cases A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2019; 14():227-239. PubMed ID: 30697043
[TBL] [Abstract][Full Text] [Related]
5. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
[TBL] [Abstract][Full Text] [Related]
6. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany.
Hofer F; Achelrod D; Stargardt T
Appl Health Econ Health Policy; 2016 Dec; 14(6):691-701. PubMed ID: 27475635
[TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD.
Hoogendoorn M; Feenstra TL; Hoogenveen RT; Rutten-van Mölken MP
Thorax; 2010 Aug; 65(8):711-8. PubMed ID: 20685746
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease.
Kirsch F
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):301-16. PubMed ID: 25600470
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.
Mosher CL; Nanna MG; Jawitz OK; Raman V; Farrow NE; Aleem S; Casaburi R; MacIntyre NR; Palmer SM; Myers ER
JAMA Netw Open; 2022 Jun; 5(6):e2218189. PubMed ID: 35731514
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
13. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease.
Borg S; Ericsson A; Wedzicha J; Gulsvik A; Lundbäck B; Donaldson GC; Sullivan SD
Value Health; 2004; 7(2):153-67. PubMed ID: 15164805
[TBL] [Abstract][Full Text] [Related]
14. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
Price D; Asukai Y; Ananthapavan J; Malcolm B; Radwan A; Keyzor I
Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.
Prasitwarachot R; Thavorn K; Patikorn C; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Chaiyakunapruk N
J Med Econ; 2023; 26(1):1377-1385. PubMed ID: 37818930
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation.
Dretzke J; Blissett D; Dave C; Mukherjee R; Price M; Bayliss S; Wu X; Jordan R; Jowett S; Turner AM; Moore D
Health Technol Assess; 2015 Oct; 19(81):1-246. PubMed ID: 26470875
[TBL] [Abstract][Full Text] [Related]
17. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
18. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.
Najafzadeh M; Marra CA; Lynd LD; Sadatsafavi M; FitzGerald JM; McManus B; Sin D
PLoS One; 2012; 7(10):e46746. PubMed ID: 23071626
[TBL] [Abstract][Full Text] [Related]
19. Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care.
Lambe T; Adab P; Jordan RE; Sitch A; Enocson A; Jolly K; Marsh J; Riley R; Miller M; Cooper BG; Turner AM; Ayres JG; Stockley R; Greenfield S; Siebert S; Daley A; Cheng KK; Fitzmaurice D; Jowett S
Thorax; 2019 Aug; 74(8):730-739. PubMed ID: 31285359
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
